Physician

Rawan Faramand, M.D

According to 2025 Medicare claims, Rawan Faramand, M.D (NPI: 1972879955) practices hematopoietic cell transplantation and cellular therapy in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (NPI: 1306833595; TIN: 593238640) and primary practice location at 33612-9416.

Faramand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 40 traditional Medicare patients, billed 268 HCPCS/CPT codes, and received $19,668 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 686 prescription claims across 60 beneficiaries totaling $1,509,071 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 62 claims. Open Payments data shows 13 records totaling $18,527. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,953 to $1,509,071. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	21	78	$6,553
2020	58	317	$27,189
2021	60	332	$29,247
2022	53	278	$22,214
2023	55	225	$20,380
2024	40	268	$19,668

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	21	75	$1,953
2016	21	41	$1,695
2017	36	62	$4,701
2018	53	119	$43,032
2019	26	86	$41,923
2020	25	246	$71,024
2021	34	313	$60,416
2022	47	307	$226,948
2023	56	440	$558,852
2024	60	686	$1,509,071

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	13	$4,181
2021	N/R	63	$5,388
2022	N/R	45	$1,250
2023	N/R	11	$183
2024	N/R	62	$1,713

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	27	107	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	30	55	$79
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	20	64	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	35	1,050	$554,979
Rezurock	Belumosudil Mesylate	29	870	$515,442
Prevymis	Letermovir	14	394	$108,560
Cresemba	Isavuconazonium Sulfate	12	316	$75,014
Atovaquone	Atovaquone	56	1,662	$25,905

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7520	Sirolimus, oral, 1 mg	N	N/R	15	$754
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	22	$488
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$471

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	13	$18,527	SANOFI-AVENTIS U.S. LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rawan Faramand, M.D?

Tedicare shows public-source Medicare data for Rawan Faramand, M.D (NPI 1972879955), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rawan Faramand, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rawan Faramand, M.D?

Rawan Faramand, M.D is linked to H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (billing NPI 1306833595) in the available physician profile data.

Does Rawan Faramand, M.D have Open Payments data?

Rawan Faramand, M.D has 13 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.